Align Technology, Inc. (ALGN) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call indicates several concerns: a sequential decline in revenue, lower clear aligner volume, and a decrease in gross and operating margins. Despite some positive aspects like non-GAAP net income growth and cost-saving measures, the overall guidance is weak, with sequential declines expected and no specific details on future improvements. The Q&A section also highlighted management's reluctance to provide specifics on key issues, which could erode investor confidence. These factors suggest a negative sentiment, likely leading to a stock price decrease of -2% to -8%.
Key Financial Performance
Total Revenues $995.7 million, up 1.8% year-over-year and down 1.7% sequentially. The year-over-year increase was favorably impacted by approximately $15.6 million due to foreign exchange and higher Clear Aligner volumes.
Clear Aligner Revenues $805.8 million, up 2.4% year-over-year and slightly up sequentially. The year-over-year increase was driven by higher volume, price increases, favorable foreign exchange, and lower net deferrals, partially offset by higher discounts and product mix shift to lower-priced countries and products.
Clear Aligner Volume 648,000 cases, up 4.9% year-over-year and 0.5% sequentially. The year-over-year growth was driven by strong performance in APAC and EMEA regions, offset somewhat by North America.
Systems and Services Revenues $189.9 million, down 0.6% year-over-year and 8.6% sequentially. The year-over-year decrease was primarily due to lower scanner system sales, partially offset by higher scanner wand sales, higher nonsystem sales, and favorable foreign exchange.
Non-GAAP Operating Margin 23.9%, up 1.8 points year-over-year and 2.6 points sequentially. The increase was due to operational efficiencies and favorable foreign exchange.
Gross Margin 64.2%, down 5.5 points year-over-year and 5.7 points sequentially. The decrease was primarily due to restructuring and other noncash charges, impairment on assets held for sale, depreciation expense on assets to be disposed of other than by sale, and excess inventory write-off.
Net Income Per Share (GAAP) $0.78, down $0.77 year-over-year and $0.93 sequentially. The decrease was due to restructuring and other charges, unfavorable foreign exchange movements, and lower interest income.
Net Income Per Share (Non-GAAP) $2.61, up $0.26 year-over-year and $0.11 sequentially. The increase was due to operational efficiencies and favorable foreign exchange.
Free Cash Flow $169 million, calculated as cash flow from operations ($188.7 million) minus capital expenditures ($19.8 million).
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
iTero Lumina: New scanning technology with multi-direct capture technology, offering superior visualizations and effortless scanning. It represented over 90% of full system units in Q3.
Invisalign Palatal Expander: Continued rollout, offering a hygienic and comfortable alternative to traditional expanders, clinically effective for expansion.
ClinCheck Live Plan: Automates initial treatment plans in 15 minutes, enhancing efficiency and patient experience.
Exocad ART: Piloted in Europe, integrates orthodontics and restorative dentistry for better treatment outcomes.
Regional Growth: Double-digit Clear Aligner volume growth in APAC and EMEA regions, driven by teens, kids, and adults.
DSO Partnerships: Strong double-digit growth in EMEA and APAC regions, leveraging economies of scale and digital workflows.
Clear Aligner Volume: 648,000 cases in Q3, up 5% year-over-year, driven by international markets and teens/kids.
iTero Scanner Installations: Over 120,000 units globally, a 12% year-over-year increase.
AI-Powered Innovations: Investments in AI-powered treatment planning software and direct 3D printing of aligners to enhance efficiency and outcomes.
Localized Marketing: Focus on supporting doctors with localized marketing, education, and clinical support to navigate U.S. market headwinds.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
North American Market Challenges: The orthodontic and dental markets in North America remain mixed, with softer performance in the North American retail doctor channel. This could impact revenue growth and market share in the region.
Systems and Services Revenue Decline: Q3 Systems and Services revenues were down year-over-year and sequentially, primarily due to seasonality and lower scanner system sales. This decline could affect overall profitability and growth in this segment.
Restructuring and Noncash Charges: The company incurred significant restructuring and noncash charges, including impairment on assets held for sale and excess inventory write-offs. These charges negatively impacted gross margins and operating income.
Foreign Exchange Fluctuations: Foreign exchange fluctuations have impacted revenues and gross margins, creating uncertainty in financial performance.
Product Mix Shift: A shift to lower-priced countries and products has led to a decrease in average selling prices for Clear Aligners, which could pressure margins.
Economic and Financial Barriers: Economic conditions and financial barriers for patients, particularly in North America, could limit the adoption of Invisalign treatments, despite efforts to increase affordability through partnerships.
Supply Chain and Inventory Challenges: Excess inventory write-offs and lower scanner wand sales indicate potential inefficiencies in supply chain and inventory management.
Regulatory and Tax Changes: Changes in U.K. VAT and U.S. tariffs have required adjustments in pricing and operations, adding complexity and potential cost pressures.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Q4 2025 Revenue: Expected to be in the range of $1.025 billion to $1.045 billion, up sequentially from Q3 2025.
Q4 2025 Clear Aligner Volume and ASP: Expected to increase sequentially due to favorable geographic mix.
Q4 2025 Systems and Services Revenue: Expected to increase sequentially, consistent with typical Q4 seasonality.
Q4 2025 GAAP Gross Margin: Expected to be 65.5% to 66%, up sequentially due to higher revenue and lower restructuring charges.
Q4 2025 Non-GAAP Gross Margin: Expected to be approximately 71%.
Q4 2025 GAAP Operating Margin: Expected to be 15.3% to 15.8%, up sequentially due to lower restructuring charges.
Q4 2025 Non-GAAP Operating Margin: Expected to be approximately 26%.
Fiscal 2025 Clear Aligner Volume Growth: Expected to grow mid-single digits.
Fiscal 2025 Revenue Growth: Expected to be flat to slightly up from 2024, assuming current foreign exchange rates.
Fiscal 2025 GAAP Operating Margin: Expected to be around 13.6% to 13.8%, down year-over-year due to restructuring and noncash charges.
Fiscal 2025 Non-GAAP Operating Margin: Expected to be slightly above 22.5%.
Fiscal 2025 Capital Expenditures: Expected to be approximately $100 million, primarily for technology upgrades.
Fiscal 2026 Operating Margin Improvement: Expected to improve by at least 100 basis points year-over-year due to restructuring actions and other initiatives.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: During Q3, the company repurchased approximately 0.5 million shares of its common stock at an average share price of $136.77. These repurchases were made pursuant to the $200 million open market repurchase plan announced on August 5, 2025, which is expected to be completed in January of 2026. As of September 30, 2025, $928.4 million remains available for repurchase of common stock under the previously announced April 2025 repurchase program.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you comment on any early 4Q trends and the impact of the new ClinCheck launch on gross margins?
A:The management expressed optimism about the third quarter and highlighted the comprehensive technology of ClinCheck, which aims to improve efficiency for doctors and enhance patient communication. However, no specific details on early 4Q trends or gross margin impacts were provided.
Q:Why was ASP down in Q3 instead of being up as expected, and what will drive sequential improvement in Q4?
A:ASP was down in Q3 due to growth in markets like China with lower ASPs compared to Europe. In Q4, Europe’s higher ASP will have a larger impact as it comes out of the holiday season, while China’s contribution will decrease. This geographic mix will drive sequential improvement.
Q:What are your thoughts on the pricing environment and the potential rollout of the no refinement plan?
A:The no refinement plan is seen as an evolution in serving doctors, allowing them to address cases with fewer aligners. Management emphasized the improvement in technology and confidence among doctors but did not provide specific timing for the rollout.
Q:Can you provide high-level commentary on the top line for next year and the margin outlook for 2026?
A:Management highlighted strong global growth, particularly in 9 of the top 10 countries, but noted challenges in North America retail. They refrained from making specific predictions for 2026 but expressed confidence in their margin projections.
Q:What is the biggest factor affecting North America retail customers, and what is Align doing to address it?
A:Economic issues are the primary challenge for North America retail customers. Align is focusing on marketing, advertising, and leveraging its brand to drive patient traffic to doctors. They are also using their field force to support retail customers.
Q:Can you confirm double-digit year-over-year growth in EMEA and APAC, and provide more details on North America case volumes?
A:Management confirmed double-digit year-over-year growth in EMEA and APAC, driven by strong performance in countries like India and Turkey. They did not provide specific numbers for North America but acknowledged challenges in retail case volumes.
Q:What is driving growth in the teen segment, and is the shift back to wires and brackets over?
A:Teen growth was driven by strong performance in China, new products like IPE and mandibular advancement, and early intervention technologies. Management believes the shift back to wires and brackets is diminishing as their technology gains traction.
Q:What percentage of your business is DSOs, and why are they performing better?
A:DSOs account for approximately 25% of the business. They are performing better due to their focus on digital orthodontics, patient visualization, competitive pricing, and financing options like HFD.
Q:What is the status of the HFD patient financing partnership?
A:The HFD partnership is progressing well, with increasing adoption by doctors and DSOs. It is helping patients decide on treatment by addressing pricing concerns and monthly payment options.
Q:What is the competitive landscape in China, and how are you preparing for VBP?
A:Management is aware of the potential implementation of VBP in China but noted that details are unclear. They are positioning themselves by structuring their portfolio to address Tier 3 and Tier 4 cities.
Q:What is causing the geographic mix shift in ASP, and how does FX impact it?
A:ASP fluctuations are primarily due to geographic mix, with lower ASPs in emerging markets like China. FX had a minor impact, and like-for-like ASPs in Europe and the U.S. were up quarter-over-quarter.
Q:Are you still confident in your 5%-15% growth targets, and is mid-single-digit growth possible next year?
A:Management reaffirmed their confidence in the 5%-15% growth targets but did not specifically confirm mid-single-digit growth for next year.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on early 4Q trends, gross margin impacts of ClinCheck, and the timing of the no refinement plan rollout. They also refrained from giving precise numbers for North America case volumes and predictions for 2026.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ART
America Latin
CAD
Clear Aligners
DSO
Digital
Invisalign Palatal
Invisalign treatment
Palatal Expander
Palatal expander
Services revenue
addition
asset sale
charge impairment
country product
depreciation asset
depreciation expense
doctor Invisalign
exchange revenue
exocad
expense asset
impairment asset
impairment loss
inventory depreciation
inventory write
item impairment
loss asset
loss inventory
noncash charge
noncash item
option
point restructuring
restructuring noncash
retention
sale depreciation
sale impairment
shift country
tooth
treatment planning
ALGN Transcript
Align Technology, Inc. (ALGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-8
Align Technology, Inc. (ALGN) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Neutral6-4
Align Technology, Inc. (ALGN) Presents at 46th Annual William Blair Growth Stock Conference Prepared Remarks Transcript
Neutral6-3
Align Technology, Inc. (ALGN) Presents at Stifel Jaws & Paws Conference 2026 Transcript
Neutral5-28
ALGN Slides
ALGN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
